Fig. 1: SARS-CoV-2 infection status, viral shedding and COVID-19 symptoms of recruited patients.
a, Patients with cancer irrespective of cancer type, stage or treatment were recruited. Follow-up schedules for patients with cancer were bespoke to their COVID-19 status and account for their clinical schedules (inpatients, every 2–14 d; outpatients, every clinical visit maximum every 3–6 weeks in year one and every 6 months in year two and at the start of every or every second cycle of treatment). Clinical data, ONP swabs and blood were collected at each study visit. Viral antigen testing (RT–PCR on swabs), antibody (ELISA and flow cytometric assay), T cell response and IFN-γ activation assays were performed. b, Distribution of SARS-CoV-2 infection and S1-reactive antibody status and COVID-19 severity in patients with cancer. In total, 357 patients with cancer were recruited between 4 May 2020 and 31 March 2021. SARS-CoV-2 infection status by RT–PCR and S1-reactive antibodies were analyzed at recruitment and in serial samples. RT–PCR results before recruitment were extracted from electronic patient records. The COVID-19 case definition included all patients with either RT–PCR-confirmed SARS-CoV-2 infection or S1-reactive antibodies. c, Viral shedding in 43 patients with serial positive swabs. Solid bars indicate time to the last positive test and dotted lines denote the time from the last positive test to the first negative test. d, Distribution of symptoms in 118 patients with COVID-19. Bar graph denotes the number of patients. Each row in the lower graph denotes one patient. ONP, oronasopharyngeal; WGS, whole-genome sequencing; RTx, radiotherapy; HSCT, human stem cell transplant; GI, gastrointestinal.
